

## ORAL ABSTRACTS

**538. A Retrospective Study to Evaluate the Safety of Switching Antiretroviral Therapy (ART) to Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine (RPV/TDF/FTC) STR in Virologically Suppressed HIV-Infected Patients**

Ana Monczor, MD<sup>1</sup>; Xiaoying Yu, MD, MS<sup>2</sup>; Karen J. Vigil, MD<sup>3</sup>; Claudia Kozinetz, PhD, MPH<sup>4</sup>; Roberto Arduino, MD<sup>5</sup>; <sup>1</sup>FUNCEI - Fundacion Centro de Estudios Infectologicos, Buenos Aires, Argentina; <sup>2</sup>Baylor College of Medicine and Study Design and Analysis Core, Baylor-UTHouston Center for AIDS Research, Houston, TX; <sup>3</sup>The University of Texas Health Science Center at Houston, Houston, TX; <sup>4</sup>Department of Pediatrics, Baylor College of Medicine and Study Design and Analysis Core, Baylor-UTHouston Center for AIDS Research, Houston, TX; <sup>5</sup>Infectious Diseases, The University of Texas Health Science, Houston, TX

**Session:** 64. HIV Antiretroviral Therapy  
*Thursday, October 9, 2014: 2:00 PM*

**Background.** Recent clinical trials have shown that switching from PI/r or NNRTI to RPV/TDF/FTC is safe and effective in virologically suppressed HIV-infected patients. In this study, we assessed the tolerability, metabolic profile, maintenance of virologic suppression and changes in renal function after switching to RPV/TDF/FTC in a clinical setting.

**Methods.** Retrospective chart review of HIV-infected individuals on stable ART for at least 6 months and HIV RNA levels <200 copies/mL whose ART was switched to RPV/TDF/FTC for simplicity, dyslipidemia or ARV intolerance. Wilcoxon signed

rank tests and paired t tests were used to test the changes of the lab results and 10-year cardiovascular risk.

**Results.** 162 out of 175 subjects were analyzed at week 6 ± 4 (n = 140), 24 ± 8 (n = 137) and 48 ± 8 (n = 139). 33% were female; 32% African-American and 57% Hispanic/Latino. Baseline ARV regimen contained NNRTI in 55% and PI/r in 41% of subjects. 18 (11%) of 162 subjects discontinued RPV/TDF/FTC: 3 (2%) due to virologic failure (HIV RNA ≥200 copies/mL) and 6 (4%) grade ≥3 adverse event (2 CNS symptoms, 2 liver toxicity, 1 pancreatitis and 1 acute renal failure). Adverse events occurred in 19 (12%) subjects: 10 reported CNS symptoms, 4 liver toxicity, 2 acute renal failures and 1 each of CV event, pancreatitis and cutaneous reaction. 7 subjects developed virologic failure; 3 subjects continued RPV/TDF/FTC achieving re-suppression.

There was significant improvement (mean ± SD, -0.41 ± 1.54, P = 0.04) in 10-year Framingham Cardiovascular Risk score (%) from baseline (4.57 ± 5.01) to week 24 (4.16 ± 4.71). Mean (SD) changes from baseline in creatinine were 0.03 mg/dL (0.15) at week 24 (P = 0.02).

Median (Interquartile Range) changes from baseline in fasting lipid parameters (mg/dL)

Visit	Baseline	Week 24	Change from Baseline	P (Wilcoxon signed rank test)
Total Cholesterol	183 (163 , 212)	161 (145 , 183)	-20 (-38 , -1)	<0.0001
LDL-Cholesterol	106 (88 , 129)	99 (82 , 119)	-8 (-22 , 9)	<0.0001
HDL-Cholesterol	43 (35 , 54)	39 (33 , 47)	-4 (-10 , 2)	<0.0001
Triglycerides	147 (106 , 247)	112 (78 , 161)	-34 (-97 , -6)	0.006

**Conclusion.** Switching to RPV/TDF/FTC resulted in significant improvement in lipid profile leading to a decrease in 10-year Framingham Risk score at week 24. It was well tolerated with low rates of discontinuation due to adverse events.

**Disclosures.** All authors: No reported disclosures.